Quarterly report pursuant to Section 13 or 15(d)

Revenues - Additional Information (Detail)

v3.3.0.814
Revenues - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Deferred Revenue Arrangement [Line Items]        
Revenues from product sales     $ 0  
Allergan Inc [Member] | Collaborative Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, license revenue     0 $ 0
Allergan Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments $ 13,000,000   13,000,000  
Daiichi Sankyo Inc [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 400,000 $ 0 400,000 1,100,000
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 91,100,000   91,100,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 2,600,000   2,600,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 37,400,000   37,400,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 50,200,000   50,200,000  
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 900,000   900,000  
Sanofi [Member] | Maximum [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 51,600,000   51,600,000  
Sanofi [Member] | Maximum [Member] | Research Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 1,900,000   1,900,000  
Sanofi [Member] | Maximum [Member] | Development Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 29,600,000   29,600,000  
Sanofi [Member] | Maximum [Member] | Commercial Milestones [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, milestone payments 20,100,000   20,100,000  
Sanofi [Member] | Collaborative Arrangement [Member]        
Deferred Revenue Arrangement [Line Items]        
Collaboration agreement, revenue recognized $ 0 $ 0 $ 0 $ 700,000